Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Olympus Acquires Stryker OP-1 Products, Spawns Biotech Division

This article was originally published in The Gray Sheet

Executive Summary

Olympus Corp. is forming a new business focused on regenerative medicine product offerings following the Dec. 6 purchase of Stryker Biotech's OP-1 orthopedic bone protein business for $60 million.

You may also be interested in...



News In Brief

Industry guides on ethical distribution pacts. Stryker settles charges over OP-1 marketing. Terumo buys Onset Medical. More news briefs.

Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz

Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.

Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz

Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT029677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel